SAN FRANCISCO--(BUSINESS WIRE)--Jan. 17, 2006--Theregen Company, a regenerative medicine company, has received $1.5 million from Sanderling Ventures to fund clinical development of Anginera(TM), its lead heart therapy product. The U.S. Food and Drug Administration has approved Theregen’s Investigational New Drug (IND) application to conduct a Phase I safety trial of Anginera in patients with acute myocardial ischemia. Theregen plans to initiate the Phase I study in early 2006.
